METHODOLOGY OF RENAL SCINTIGRAPHY WITH ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR

被引：0
|
作者：
BAULIEU, F
RAMACKERS, JM
MURE, A
COSCULLELA, S
JEANDOT, R
PERDRISOT, R
BAULIEU, JL
LECLOIREC, J
机构：
[1] CHU TOURS,SERV MED NUCL IN VIVO & ULTRASONS,F-37044 TOURS,FRANCE
[2] SERV EXPLORAT ISOTOP,F-69473 LYON,FRANCE
[3] HOP ST ANTOINE,NUCL MED SERV,F-75571 PARIS,FRANCE
[4] CHU PELLEGRIN,NUCL MED SERV,F-33076 BORDEAUX,FRANCE
[5] CHU LIMOGES,NUCL MED SERV,F-87042 LIMOGES,FRANCE
[6] CTR EUGENE MARQUIS,NUCL MED SERV,F-35062 RENNES,FRANCE
来源：
MEDECINE NUCLEAIRE | 1995年 / 19卷 / 5-6期
关键词：
ANGIOTENSIN CONVERTING ENZYME INHIBITOR; CAPTOPRIL; ARTERIAL HYPERTENSION; RENOVASCULAR HYPERTENSION; KIDNEY; METHODOLOGY;
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
This methodological paper is based upon the data in the literature concerning the renal scintigraphy following angiotensin converting enzyme inhibition in the diagnosis of renovascular hypertension. After briefly recalling the pathophysiological considerations necessary for understanding the test, we reviewed the current knowledge about the handling of different radiopharmaceutical agents, the patient preparation, the radionuclide scan procedure, and finally examined proposed parameters for test interpretation.
引用
下载
收藏
页码：289 / 299
页数：11
相关论文
共 50 条
  • [41] ANTITUSSIVE EFFECT OF CAPTOPRIL, AN ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR, IN THE RAT
    KAMEI, J
    IGARASHI, H
    IWAMOTO, Y
    TANIHARA, H
    MISAWA, M
    KASUYA, Y
    RESEARCH COMMUNICATIONS IN CHEMICAL PATHOLOGY AND PHARMACOLOGY, 1993, 81 (03): : 293 - 298
  • [42] LIMITATION OF EXPERIMENTAL INFARCT SIZE BY AN ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR
    ERTL, G
    KLONER, RA
    ALEXANDER, RW
    BRAUNWALD, E
    CIRCULATION, 1982, 65 (01) : 40 - 48
  • [43] ACUTE AND SUBCHRONIC TOXICITY OF A NONSULFHYDRYL ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR
    LAROCCA, PT
    SQUIBB, RE
    POWELL, ML
    SZOT, RJ
    BLACK, HE
    SCHWARTZ, E
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 1986, 82 (01) : 104 - 111
  • [44] PHARMACOLOGICAL PROFILE OF TRANDOLAPRIL, A NEW ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR
    CONEN, H
    BRUNNER, HR
    AMERICAN HEART JOURNAL, 1993, 125 (05) : 1525 - 1531
  • [45] ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR THERAPY AND DIABETIC-RETINOPATHY
    JACKSON, WE
    HOLMES, DL
    GARG, SK
    HARRIS, S
    CHASE, HP
    ANNALS OF OPHTHALMOLOGY, 1992, 24 (03) : 99 - 103
  • [46] ISOLATION OF ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR FROM TUNA MUSCLE
    KOHAMA, Y
    MATSUMOTO, S
    OKA, H
    TERAMOTO, T
    OKABE, M
    MIMURA, T
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1988, 155 (01) : 332 - 337
  • [47] USE OF ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR IN DIAGNOSIS AND TREATMENT OF HYPERTENSION
    GAVRAS, H
    BRUNNER, HR
    LARAGH, JH
    GAVRAS, I
    VUKOVICH, RA
    CLINICAL SCIENCE AND MOLECULAR MEDICINE, 1975, 48 : S57 - S60
  • [48] PREVALENCE OF COUGH DURING ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR THERAPY
    GOLDSZER, RC
    LILLY, LS
    SOLOMON, HS
    AMERICAN JOURNAL OF MEDICINE, 1988, 85 (06): : 887 - 887
  • [49] EFFICACY AND SAFETY OF CILAZAPRIL, A NEW ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR
    GOLDSZER, RC
    RODRIGUEZ, R
    SOLOMON, HS
    AMERICAN JOURNAL OF HYPERTENSION, 1988, 1 (03) : S300 - S302
  • [50] REDUCED MYOCARDIAL EXPANSION WITH THE ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR ENALAPRIL
    SHATKIN, BJ
    SWINFORD, RD
    HONIG, SC
    COHN, PF
    BROWN, EJ
    CIRCULATION, 1985, 72 (04) : 316 - 316
12345